Brazil ANVISA SaMD Regulation Update: Preparing for Changes to RDC 657/2022

Health Canada Ministerial Reliance Order: Faster Market Access for Medical Devices

Health Canada has introduced a new Ministerial Reliance Order, effective July 15, 2026, designed to accelerate market access for medical devices and drugs. This episode breaks down how the new reliance pathway allows manufacturers to leverage approvals from trusted foreign regulators to expedite the Canadian review process. We discuss the potential eligibility criteria, the critical public consultation period ending on September 12, 2026, and provide practical, actionable steps for regulatory and quality teams to prepare their submission strategies. Key Questions: - What is Health Canada's new Ministerial Reliance Order? - How does this order accelerate the review process for medical devices? - Which foreign regulatory approvals will Health Canada likely recognize? - What are the potential eligibility criteria for devices under this new pathway? - Why is the September 12, 2026, deadline for public consultation so important? - How can manufacturers prepare their submissions to leverage this reliance route? - What documentation is needed to demonstrate equivalence with a foreign approval? - What are the immediate implications of this order for your Canadian market access strategy? - Should you re-prioritize Canada in your global launch sequence? Sources: - https://www.canada.ca/en/health-canada/news/2026/07/helping-canadians-access-safe-effective-treatments-and-medicines-faster.html How Pure Global can help: Navigating new regulatory pathways like Health Canada's Ministerial Reliance Order requires local expertise and a clear strategy. Pure Global provides end-to-end support for MedTech and IVD companies, acting as your local representative and developing efficient pathways for regulatory approval in Canada and over 30 other markets. Our experts use advanced AI to compile and manage technical dossiers, ensuring your submissions are optimized for accelerated review. Let us help you leverage your existing approvals to access the Canadian market faster. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

UK MHRA Draft Medical Device Regulations 2026: Key Changes and Timeline

This episode covers the closing of the WTO comment period on July 7, 2026, for the UK MHRA's draft Medical Devices (Amendment) Regulations 2026. We break down the key changes manufacturers need to prepare for, including the new international reliance pathway for approvals from other major regulators, the implementation of a UK-specific Unique Device Identification (UDI) system, and the significant shift to a risk-based classification system for In-Vitro Diagnostics (IVDs). We also discuss the expected timeline for these regulations to become law in late 2026 and provide practical steps for regulatory and quality teams to begin their transition planning. Key Questions: - What does the closing of the WTO comment period on July 7, 2026, mean for the UK's new medical device rules? - How will the proposed international reliance pathway change market access strategy for Great Britain? - What are the key details of the UK's planned Unique Device Identification (UDI) system? - How will In-Vitro Diagnostic (IVD) devices be reclassified under the new risk-based framework? - What is the expected timeline for the 2026 regulations to become law? - What steps should regulatory teams take now to prepare for these significant changes? - How do the new rules affect software as a medical device (SaMD) and implantable devices? Sources: - https://www.dacbeachcroft.com/en/gb/articles/2026/june/mhra-publishes-draft-regulations-for-medical-device-reform/ - https://www.gov.uk/government/news/mhra-invites-views-on-proposed-changes-to-medical-device-regulation - https://www.pinsentmasons.com/out-law/news/mhra-publishes-draft-2026-medical-device-regulations-for-gb-market - https://www.linkedin.com/pulse/mhra-publishes-draft-amendment-uk-medical-devices-regulations-dpcnf How Pure Global can help: Pure Global offers end-to-end regulatory consulting to help MedTech and IVD companies navigate complex market transitions like the UK's new 2026 regulations. Our experts develop efficient regulatory strategies, leveraging new pathways like international reliance to accelerate your market access. We act as your local UK Responsible Person, manage technical dossier compilation using advanced AI, and provide continuous regulatory monitoring to ensure ongoing compliance. Whether you're a startup or a multinational, we streamline your path to the UK market. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and regulatory database at https://pureglobal.ai to get started.

EU REP Symbol Transition: Compliance Guide for Medical Device Labeling by 2031

This episode details the formal transition from the 'EC REP' to the 'EU REP' symbol for European Authorized Representatives on medical device and IVD labeling. We discuss the implications of the amended harmonized standard EN ISO 15223-1:2021/A1:2025, published on June 17, 2026. The host explains the 60-month transition period, which ends on June 17, 2031, and provides practical, actionable steps for manufacturers to update their technical documentation, QMS, labeling, and packaging to ensure continued compliance in the European Union. Key Questions: - What is the significance of the EU REP symbol change? - When is the official deadline to stop using the EC REP symbol? - Does this change affect both medical devices and IVDs? - What specific standard was updated to formalize this transition? - How long is the transition period for implementing the new EU REP symbol? - What are the first steps a manufacturer should take to manage this change? - How does this labeling update impact technical documentation and the QMS? - Should manufacturers coordinate this change with their Notified Body? - Can both the EC REP and EU REP symbols be used simultaneously during the transition? - What is a practical strategy for updating packaging and labeling across a large product portfolio? Sources: - https://www.medqair.com/medical-device-regulatory-news/ec-rep-to-eu-rep-what-the-ojeu-publication-means-in-practice - https://www.decomplix.com/regulatory-news/ - https://www.pure-global.com/regulatory-updates How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, develop efficient regulatory strategies, and use advanced AI to compile and manage technical dossiers for submission. Our team of local experts helps you navigate complex requirements like labeling changes to ensure your products remain compliant and reach markets faster. For support with your EU regulatory strategy and technical file updates, contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and regulatory database at https://pureglobal.ai.

Saudi Arabia SFDA Medical Device Bundling: Key Changes in Guidance MDS-G-028

Saudi Arabia's SFDA has released a new guidance document, MDS-G-028, effective May 3, 2026, which significantly changes the rules for bundling medical devices. This episode breaks down the updated criteria for grouping devices into families, systems, and procedure packs for a single Medical Device Marketing Authorization (MDMA). We discuss the impact on submission strategies, costs, and documentation requirements, and provide practical steps for manufacturers to ensure compliance and maintain market access. Key Questions: - What is the new SFDA guidance MDS-G-028 on medical device bundling? - How does MDS-G-028 change the rules for creating a "device family" in Saudi Arabia? - What are the updated definitions for "systems" and "procedure packs"? - How will these changes affect MDMA submission costs and timelines for manufacturers? - What new documentation is required to justify a device grouping to the SFDA? - Which types of medical device companies are most affected by these new rules? - What are the implications for existing MDMAs upon renewal? - What practical steps should regulatory teams take now to prepare for this change? Sources: - https://www.complianceandrisks.com/blog/gcc-medical-devices-regulation-2026-updates-for-manufacturers/ - https://www.sfda.gov.sa/sites/default/files/2024-05/MDS-G-028.pdf - https://www.sfda.gov.sa/en/medical-devices How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex global markets like Saudi Arabia. Our team of local experts, supported by advanced AI, can help you develop a compliant regulatory strategy, prepare robust technical dossiers, and act as your local representative. We streamline the market access process, helping you manage submission strategies and ensure compliance with new requirements like MDS-G-028. For support with your global expansion and to access our free AI regulatory tools and database, visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our tools at https://pureglobal.ai.

Australia TGA UDI Requirements: High-Risk Device Compliance by July 1, 2026

Australia's Therapeutic Goods Administration (TGA) is implementing mandatory Unique Device Identification (UDI) requirements for high-risk medical devices starting July 1, 2026. This episode details the compliance obligations for manufacturers and sponsors of Class IIb and Class III devices. We cover the core requirements for UDI assignment, labeling, and data submission to the Australian UDI Database (AusUDID), and explain how the TGA will assess compliance during pre-market review. We also provide practical steps for regulatory and quality teams to prepare for this critical market access deadline. Key Questions: - What are the new TGA UDI requirements for high-risk medical devices? - When is the compliance deadline for Class IIb and Class III devices in Australia? - How will the TGA assess UDI compliance in pre-market applications? - What information must be submitted to the Australian UDI Database (AusUDID)? - What are the first steps manufacturers should take to prepare for the July 1, 2026 deadline? - How does Australia's UDI system compare to those in the US and EU? - Which UDI issuing agencies are recognized by the TGA? - What are the future UDI deadlines for lower-risk devices? Sources: - https://www.tga.gov.au/news/news/new-udi-requirements-medical-devices-commence-1-july-2026 How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, accelerating global market access. We act as your local representative and manage device registrations in over 30 countries, including Australia. Our experts develop efficient regulatory strategies and use advanced AI to compile and submit technical dossiers, minimizing delays. We help you navigate complex requirements like the TGA's UDI implementation, ensuring your products remain compliant from initial submission through post-market surveillance. Visit https://pureglobal.com or contact us at info@pureglobal.com to learn more. Explore our free AI tools and regulatory database at https://pureglobal.ai.